Document ID: FDA-2013-N-1041-0004
Agency: fda
Document Type: Notice
Title: Fibromyalgia Public Meeting on Patient-Focused Drug Development;
Rescheduling of Public Meeting; Extension of Comment Period
Posted Date: 2014-02-19T05:00Z

[Federal Register Volume 79, Number 33 (Wednesday, February 19, 2014)]
[Notices]
[Pages 9468-9469]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-03587]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-N-1041]

Fibromyalgia Public Meeting on Patient-Focused Drug Development; 
Rescheduling of Public Meeting; Extension of Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; rescheduling of public meeting; extension of comment 
period.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is rescheduling a 
December 10, 2013, public meeting on Patient-Focused Drug Development 
for fibromyalgia, announced in the Federal Register on September 23, 
2013. Due to inclement weather, the Federal Government was closed on 
December 10, 2013. We are rescheduling the public meeting to March 26, 
2014, and extending the comment period for the public docket.

DATES: The public meeting will be held on March 26, 2014, from 1 p.m. 
to 5 p.m. Registration to attend the meeting must be received by March 
20, 2014. See the SUPPLEMENTARY INFORMATION section for information on 
how to register for the meeting. Submit either electronic or written 
comments by May 27, 2014.

ADDRESSES: The meeting will be held at the FDA White Oak Campus, 10903 
New Hampshire Ave., Building 31 Conference Center, Sections B and C of 
the Great Room (rm. 1503), Silver Spring, MD 20993. Entrance for the 
public meeting participants is through Building 1, where routine 
security check procedures will be performed. For more information on 
parking and security procedures, please refer to http://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm.
    Submit electronic comments to http://www.regulations.gov. Submit 
written comments to the Division of Dockets Management (HFA-305), Food 
and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 
20852. All comments should be identified with the docket number found 
in brackets in the heading of this document.
    FDA will post the agenda approximately 5 days before the meeting at 
http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm363203.htm.

FOR FURTHER INFORMATION CONTACT: Graham Thompson, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 51, rm. 1199, Silver Spring, MD 20993, 301-796-
5003, FAX: 301-847-8443, email: Graham.Thompson@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In the Federal Register of September 23, 
2013 (78 FR 58313), FDA announced a public meeting on December 10, 
2013, to obtain patients' perspectives on the impact of fibromyalgia on 
daily life as well as the available therapies for fibromyalgia. Due to 
the Government closure on December 10, 2013, the meeting was postponed. 
We are rescheduling the public meeting to March 26, 2014, and extending 
the comment period to May 27, 2014 (see

[[Page 9469]]

DATES). For additional information about the purpose of the meeting, 
topics for discussion, and registration see the September 23, 2013, 
Federal Register notice.

    Dated: February 13, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-03587 Filed 2-18-14; 8:45 am]
BILLING CODE 4160-01-P